Lantheus stock saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.
The new score tells you the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
Lantheus stock is currently extended beyond a proper buy zone after breaking out from a 73.88 entry in a cup without handle. Wait for the medical stock to pull back and form a pattern for another buying opportunity.
See How IBD Helps You Make More Money In Stocks
Lantheus stock sports an 80 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q2, the medical diagnostic products maker posted 709% earnings-per-share growth. Sales growth came in at 121%, down from 126% in the previous quarter.
Lantheus stock holds the No. 1 rank among its peers in the Medical-Products industry group. Staar Surgical and Repligen are also among the group's highest-rated stocks.
